In May 2020, the inclusion of a biomarker was approved for nivolumab in the treatment of adult patients with metastatic or recurrent NSCLC whose tumors express PD-L1 (≥ 1%) as determined by an FDA-approved test (66). Here, CD274 is linked to non-small cell lung carcinoma.